Evidence map›Paper›PMID 16087754›Full record

ArticleEukaryotic cell2005

Candida albicans biofilm-defective mutants.

Mathias L Richard, Clarissa J Nobile, Vincent M Bruno, Aaron P Mitchell

Open access · diamondAbstract read
In one paragraph

Article in Eukaryotic cell, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 156 citations in OpenAlex.

  1. Article
  2. Review
  3. Optimization of in vitro Biofilm Growth ofIndian journal of microbiology · 2025
    Article
  4. Roles of P-body factors inbioRxiv : the preprint server for biology · 2025
    Article
  5. Article
  6. Strain background ofMicrobiology (Reading, England) · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. AIMS microbiology · 2023
    Review
  11. Application of the Mutant Libraries forInternational journal of molecular sciences · 2022
    Review
  12. Antifungal Activity of the Frog Skin Peptide Temporin G and Its Effect onInternational journal of molecular sciences · 2022
    Article
  13. Virulence · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Cell Surface Expression of Nrg1 Protein inJournal of fungi (Basel, Switzerland) · 2021
    Article
  19. Critical reviews in microbiology · 2021
    Review
  20. The Transcription Factor Stp2 Is Important forFrontiers in microbiology · 2020
    Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mathias L RichardDepartment of Microbiology, Columbia University, New York, NY 10032, USA.
Clarissa J Nobile
Vincent M Bruno
Aaron P Mitchell
Columbia University · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
TRAINING PROGRAM IN MICROBIOLOGY FOR INFECTIOUS DISEASEST32AI007161 · NIAID · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI FIDOCK, DAVID A · 1985 to 2008
$1.9M
C. albicans Regulatory Pathways in Oral CandidiasisR01AI050931 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MITCHELL, AARON P · 2001 to 2005
$1.5M
PATHOBIOLOGY OF GI INFECTION AND INFLAMATIONT32DK007786 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GERSHON, MICHAEL D · 2001 to 2005
$766k
CONFOCAL IMAGING FACILITYS10RR010506 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PON, LIZA A · 1996 to 1996
–
BIORAD 2-PHOTON LASER SCANNING MICROSCOPY SYSTEMS10RR013701 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KRIEGSTEIN, ARNOLD · 1999 to 1999
–
NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA13696NCRR NIH HHS S10 RR10506NCRR NIH HHS S10 RR13701NIAID NIH HHS R01 AI050931NIAID NIH HHS R01 AI50931NIAID NIH HHS T32 AI007161NIAID NIH HHS T32 AI07161NIDDK NIH HHS T32 DK007786
6 · The paper itself

Abstract

Biofilm formation plays a key role in the life cycles and subsistence of many microorganisms. For the human fungal pathogen Candida albicans, biofilm development is arguably a virulence trait, because medical implants that serve as biofilm substrates are significant risk factors for infection. The development of C. albicans biofilms in vitro proceeds through an early phase, in which yeast cells populate a substrate, an intermediate phase, in which pseudohyphal and hyphal cell types are produced, and a maturation phase, in which continued cell growth is accompanied by accumulation of an extracellular matrix. Here we report the results of a screen for C. albicans biofilm-defective mutants, in which homozygous insertions in NUP85, MDS3, KEM1, and SUV3 were found to block biofilm development. Confocal microscopic examination suggests that nup85, suv3, and mds3 mutations cause early-phase arrest, whereas the kem1 mutation causes intermediate-phase arrest. All of the mutants are defective in hypha production in several media. Analysis of mixed-biofilm development indicates that all of the mutants are defective in the production of hyphae in the context of a biofilm. Because all of the mutants are defective in the retention of cells in the biofilm, we infer that hyphae provide an adherent scaffold that stabilizes the biofilm structure.

Indexed as

AllelesBiofilmsCandida albicansDEAD-box RNA HelicasesExoribonucleasesGenotypeGreen Fluorescent ProteinsHyphaeMicroscopy, FluorescenceMutationNuclear Pore Complex ProteinsOpen Reading FramesRNA HelicasesSaccharomyces cerevisiae ProteinsDEAD-box RNA HelicasesExoribonucleasesGFP10 ProteinGreen Fluorescent ProteinsNuclear Pore Complex ProteinsNUP85 protein, S cerevisiaeRNA HelicasesSaccharomyces cerevisiae ProteinsSUV3 protein, S cerevisiaeXRN1 protein, S cerevisiae

Identifiers

PMID16087754
PMCPMC1214533
OpenAlexW2112987407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.